Pfizer Inc. (PFE)
Pfizer Inc. is a multinational pharmaceutical company based in New York City. It is one of the largest pharmaceutical companies in the world, with a wide range of products, including prescription drugs, consumer healthcare products, and biologic products. Pfizer is known for its research and development efforts, including the development of the COVID-19 vaccine.
Company Info
US7170811035
717081103
Aug 13, 2012
Highlights
$128.49B
$1.42
15.92
0.57
$62.46B
$42.09B
$16.71B
$20.53 - $29.98
$29.50
2.03%
2.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Pfizer Inc. (PFE) returned -10.86% year-to-date (YTD) and -15.78% over the past 12 months. Over the past 10 years, PFE returned 0.61% annually, underperforming the S&P 500 benchmark at 10.87%.
PFE
-10.86%
5.56%
-4.64%
-15.78%
-4.34%
0.61%
^GSPC (Benchmark)
1.30%
12.94%
1.49%
12.48%
15.82%
10.87%
Monthly Returns
The table below presents the monthly returns of PFE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 1.61% | -0.34% | -4.12% | -3.67% | -4.69% | -10.86% | |||||||
| 2024 | -4.52% | -1.92% | 4.48% | -7.68% | 13.55% | -2.37% | 10.69% | -5.01% | -0.24% | -2.21% | -5.95% | 1.22% | -2.22% |
| 2023 | -13.03% | -8.13% | 0.57% | -4.68% | -1.18% | -3.52% | -0.60% | -1.89% | -6.25% | -7.87% | 1.05% | -5.51% | -41.26% |
| 2022 | -10.09% | -10.91% | 10.29% | -5.22% | 8.97% | -1.15% | -2.91% | -10.45% | -3.25% | 6.38% | 8.61% | 2.21% | -10.41% |
| 2021 | -1.41% | -6.71% | 8.18% | 6.68% | 1.19% | 1.11% | 10.31% | 7.62% | -6.64% | 1.70% | 23.92% | 9.90% | 66.69% |
| 2020 | -3.98% | -10.26% | -2.33% | 17.52% | 0.55% | -14.38% | 18.83% | -1.79% | -2.88% | -3.32% | 14.98% | -3.92% | 3.07% |
| 2019 | -1.90% | 2.12% | -2.03% | -4.38% | 3.15% | 4.34% | -10.34% | -7.61% | 1.07% | 6.79% | 1.36% | 1.71% | -6.91% |
| 2018 | 2.26% | -1.06% | -2.26% | 3.16% | -0.90% | 0.97% | 10.06% | 4.87% | 6.14% | -2.29% | 8.19% | -5.58% | 24.82% |
| 2017 | -2.31% | 8.63% | 0.26% | -0.85% | -2.81% | 2.88% | -1.28% | 3.29% | 5.25% | -1.79% | 4.37% | -0.11% | 15.90% |
| 2016 | -5.55% | -1.71% | -0.10% | 10.36% | 7.03% | 1.47% | 4.77% | -4.88% | -2.67% | -6.38% | 2.37% | 1.06% | 4.42% |
| 2015 | 0.32% | 10.79% | 1.37% | -2.47% | 3.26% | -3.51% | 7.55% | -9.95% | -2.51% | 7.67% | -2.32% | -1.49% | 7.09% |
| 2014 | -0.75% | 6.51% | 0.03% | -2.62% | -4.43% | 0.17% | -2.45% | 2.40% | 0.61% | 1.29% | 4.91% | -0.00% | 5.28% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of PFE is 23, meaning it’s performing worse than 77% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Pfizer Inc. (PFE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Pfizer Inc. provided a 7.45% dividend yield over the last twelve months, with an annual payout of $1.70 per share. The company has been increasing its dividends for 12 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $1.70 | $1.68 | $1.64 | $1.60 | $1.56 | $1.44 | $1.36 | $1.29 | $1.21 | $1.14 | $1.06 | $0.99 |
Dividend yield | 7.45% | 6.33% | 5.70% | 3.12% | 2.64% | 3.91% | 3.67% | 3.11% | 3.53% | 3.69% | 3.46% | 3.33% |
Monthly Dividends
The table displays the monthly dividend distributions for Pfizer Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | $0.43 | $0.00 | $0.00 | $0.00 | $0.43 | $0.86 | |||||||
| 2024 | $0.42 | $0.00 | $0.00 | $0.00 | $0.42 | $0.00 | $0.42 | $0.00 | $0.00 | $0.00 | $0.42 | $0.00 | $1.68 |
| 2023 | $0.41 | $0.00 | $0.00 | $0.00 | $0.41 | $0.00 | $0.41 | $0.00 | $0.00 | $0.00 | $0.41 | $0.00 | $1.64 |
| 2022 | $0.40 | $0.00 | $0.00 | $0.00 | $0.40 | $0.00 | $0.40 | $0.00 | $0.00 | $0.00 | $0.40 | $0.00 | $1.60 |
| 2021 | $0.39 | $0.00 | $0.00 | $0.00 | $0.39 | $0.00 | $0.39 | $0.00 | $0.00 | $0.00 | $0.39 | $0.00 | $1.56 |
| 2020 | $0.36 | $0.00 | $0.00 | $0.00 | $0.36 | $0.00 | $0.36 | $0.00 | $0.00 | $0.00 | $0.36 | $0.00 | $1.44 |
| 2019 | $0.34 | $0.00 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.34 | $0.00 | $0.00 | $0.34 | $0.00 | $1.36 |
| 2018 | $0.00 | $0.32 | $0.00 | $0.00 | $0.32 | $0.00 | $0.00 | $0.32 | $0.00 | $0.00 | $0.32 | $0.00 | $1.29 |
| 2017 | $0.00 | $0.30 | $0.00 | $0.00 | $0.30 | $0.00 | $0.00 | $0.30 | $0.00 | $0.00 | $0.30 | $0.00 | $1.21 |
| 2016 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $0.00 | $0.28 | $0.00 | $1.14 |
| 2015 | $0.00 | $0.27 | $0.00 | $0.00 | $0.27 | $0.00 | $0.00 | $0.27 | $0.00 | $0.00 | $0.27 | $0.00 | $1.06 |
| 2014 | $0.25 | $0.00 | $0.00 | $0.25 | $0.00 | $0.25 | $0.00 | $0.00 | $0.00 | $0.25 | $0.00 | $0.99 |
Dividend Yield & Payout
Dividend Yield
Pfizer Inc. has a dividend yield of 7.45%, which means its dividend payment is significantly above the market average.
Payout Ratio
Pfizer Inc. has a payout ratio of 52.96%, which is quite average when compared to the overall market. This suggests that Pfizer Inc. strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Pfizer Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Pfizer Inc. was 58.96%, occurring on Apr 10, 2025. The portfolio has not yet recovered.
The current Pfizer Inc. drawdown is 55.78%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -58.96% | Dec 17, 2021 | 831 | Apr 10, 2025 | — | — | — |
| -35.43% | Dec 3, 2018 | 327 | Mar 23, 2020 | 177 | Dec 2, 2020 | 504 |
| -20.45% | Dec 9, 2020 | 54 | Feb 26, 2021 | 103 | Jul 26, 2021 | 157 |
| -19.22% | Aug 2, 2016 | 67 | Nov 3, 2016 | 216 | Sep 14, 2017 | 283 |
| -18.93% | Aug 4, 2015 | 130 | Feb 8, 2016 | 82 | Jun 6, 2016 | 212 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Pfizer Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Pfizer Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 36.5% positive surprise.
Valuation
The Valuation section provides an overview of how Pfizer Inc. is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for PFE, comparing it with other companies in the Drug Manufacturers - General industry. Currently, PFE has a P/E ratio of 15.9. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for PFE compared to other companies in the Drug Manufacturers - General industry. PFE currently has a PEG ratio of 0.6. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PFE relative to other companies in the Drug Manufacturers - General industry. Currently, PFE has a P/S ratio of 2.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PFE in comparison with other companies in the Drug Manufacturers - General industry. Currently, PFE has a P/B value of 1.4. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |